These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 21566413

  • 1. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
    Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ.
    Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
    [Abstract] [Full Text] [Related]

  • 2. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP, Greenberg RE, Steinberg GD.
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
    Ovesen H, Horn T, Steven K.
    J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
    Yamada Y, Hara I, Kumano M, Furukawa J, Yamanaka K, Kamidono S.
    Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG, Neulander E, Murphy WM, Wajsman Z.
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Medical management of patients with refractory carcinoma in situ of the bladder.
    Kim JC, Steinberg GD.
    Drugs Aging; 2001 Aug; 18(5):335-44. PubMed ID: 11392442
    [Abstract] [Full Text] [Related]

  • 20. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H.
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.